Komodo Health AI vs OneStream AI

Enterprise licensing to pharmaceutical companies, health systems, and payers. No public pricing. Contact for pricing.

Enterprise licensing. No public pricing. Annual contracts. Recently IPO'd (2024). Demo available.

Patient health data de-identified under HIPAA de-identification standards. Access requires data use agreements and IRB approval for research purposes. Review Komodo's data governance framework.

Financial consolidation and planning data processed on OneStream's cloud infrastructure under enterprise data handling agreements.

• ✓330 million patient longitudinal data coverage is one of the most comprehensive US real-world health datasets
• ✓Integrated claims, lab, and EHR data provides richer patient journey evidence than single-source datasets
• ✓Pulse SaaS interface makes real-world evidence accessible without custom database development
• ✓Pharmaceutical market access teams can generate regulatory-grade evidence from real-world data

• ✓Single platform for close, planning, reporting, and analytics reduces the tool proliferation in enterprise finance
• ✓Mariner AI generates financial narrative commentary reducing the manual writing burden during close cycles
• ✓2024 IPO and FedEx, Hyatt, Groupon validate across major enterprise industries
• ✓AI anomaly detection during close process reduces restatement risk from data errors

• ✕Enterprise-only licensing appropriate for pharmaceutical companies and large health systems with analytics budgets
• ✕Real-world data has limitations — claims-based patient identification is less accurate than clinical data
• ✕Regulatory acceptance of real-world evidence varies by market and indication — not a substitute for clinical trials

• ✕Enterprise complexity and pricing appropriate only for large organisations with sophisticated financial close
• ✕Implementation requires significant professional services investment and 12-18 month timelines
• ✕Competing with Oracle EPM, SAP BPC, and Workiva for enterprise financial close and planning